A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

This study is testing a new CAR T-cell therapy called CTX112 — made from donor cells rather than the patient's own cells — in people with relapsed or treatment-resistant B-cell blood cancers such as B-cell lymphoma or leukemia. **You may be eligible if...** - You are 18 or older - You have a B-cell blood cancer that has come back or stopped responding to prior treatments - Your overall health is good (ECOG 0 or 1) - Your heart, kidney, liver, and lung function are acceptable - You agree to use contraception for at least 12 months after treatment **You may NOT be eligible if...** - You have had a prior bone marrow or stem cell transplant from a donor - Your cancer involves the brain or spinal cord (CNS involvement) - You have a history of seizures, stroke, dementia, or autoimmune brain disease - You have an active, uncontrolled bacterial, viral, or fungal infection Talk to your doctor to see if this trial is right for you.